2 hours ago
4
MarketBeat
Sat, March 7, 2026 astatine 4:02 PM CST 8 min read
-
Market enactment and solution selling: CareDx said it supports much than 200 transplant centers (~80% of U.S. centers), has performed implicit 1 cardinal tests, and sees centers utilizing 3 oregon much solutions make astir doubly the investigating measurement and gross versus different customers, leveraging diagnostics, HLA kits, pharmacy services and software.
-
Strong 2025 results and equilibrium sheet: Full-year 2025 gross was $380 cardinal (up 14%) with ~200,000 tests, Q4 gross was $108 cardinal (up 25%), adjusted EBITDA $32 million, $201 cardinal successful cash, nary debt, and $88 cardinal of stock repurchases.
-
Transplant+ / AlloHeme roadmap and 2026 guidance: CareDx targets Transplant+ arsenic a ~$1 cardinal repeat-testing marketplace with AlloHeme showing median relapse detection 41 days earlier objective detection and a timeline of CLIA readiness/publication successful 2026, commercialized motorboat and sum submission successful 2027 and Medicare coverage/revenue publication successful 2028; 2026 guidance is $420–444 cardinal revenue, 220k–228k tests, and $30–45 cardinal adjusted EBITDA.
-
Interested successful CareDx, Inc.? Here are 5 stocks we similar better.
CareDx (NASDAQ:CDNA) executives outlined the company’s transplant-focused strategy, caller fiscal performance, and 2026 priorities during remarks astatine the Raymond James Institutional Investor Conference. Chief Operating Officer and precocious appointed Chief Financial Officer Keith Kennedy and Chief Commercial Officer Jessica Meng described CareDx’s presumption successful coagulated organ transplant diagnostics and services, and provided further item astir pipeline plans nether the company’s “Transplant+” roadmap.
Kennedy reiterated CareDx’s stated imaginativeness that “every diligent receives the transplant they request to unrecorded longer, fuller lives,” and described the objective discourse driving ongoing request for monitoring. He said determination are astir 100,000 patients connected the U.S. transplant waiting database and that a caller diligent is added each 8 to 10 minutes. Following coagulated organ transplant, patients are monitored regularly—often monthly oregon quarterly—for aboriginal signs of rejection, erstwhile involution is much apt to sphere graft function.
→ Uber and Joby Aviation Team Up: Game Changer oregon Hype?
CareDx described itself arsenic the marketplace person successful coagulated organ transplantation, stating it has performed much than 1 cardinal tests and astir 200,000 tests successful 2025. The institution said it supports much than 200 transplant centers successful the U.S., representing astir 80% of each transplant centers, and offers investigating services, software, diligent solutions, and distributed trial kits crossed kidney, liver, heart, lung, and multi-organ transplants.
English (CA) · 
English (US) · 
Spanish (MX) ·